Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 10

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 10
---
isable upon issuance at an exercise price of $1.60 per common share, subject to adjustment as set forth therein,
and have a 5-year term from the issuance date. The January 2024 PIPE Warrants may be exercised on a cashless basis if at the time of
exercise thereof, there is no effective registration statement registering the common shares underlying the January 2024 PIPE Warrants.
We paid the placement agent in the registered direct offering and January 2024 Private Placement a cash placement fee equal to 8.0% of
the gross proceeds received in the registered direct offering and $75,000 for reasonable legal fees and disbursements for the placement
agent’s counsel.

In connection with
the January 2024 Private Placement, the selling shareholders named in this prospectus may offer and sell up to an aggregate of 1,126,480
common shares issuable upon exercise of the January 2024 PIPE Warrants.

<div align='center'>2</div>

Implications of Being an “Emerging Growth Company” and a Foreign Private Issuer

Emerging Growth Company

We are an “emerging growth company,”
as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the JOBS Act. As such,
we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public
companies that are not “emerging growth companies” such as not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act of 2002. We could remain an “emerging growth company” for up to five years,
which will be December 31, 2027, or until the earliest of (a) the last day of the first fiscal year in which our annual gross revenue
exceeds $1.235 billion, (b) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of the securities that are
held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or
(c) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.

Foreign Private Issuer

We are subject